COVID-19 biosensing technologies.

Biosens Bioelectron

Electrical & Computer Engineering and Bioengineering Departments, UCLA, Los Angeles, CA, 90095, USA. Electronic address:

Published: April 2021

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843064PMC
http://dx.doi.org/10.1016/j.bios.2021.113046DOI Listing

Publication Analysis

Top Keywords

covid-19 biosensing
4
biosensing technologies
4
covid-19
1
technologies
1

Similar Publications

The demand for sensitive, rapid, and affordable diagnostic techniques has surged, particularly following the COVID-19 pandemic, driving the development of CRISPR-based diagnostic tools that utilize Cas effector proteins (such as Cas9, Cas12, and Cas13) as viable alternatives to traditional nucleic acid-based detection methods. These CRISPR systems, often integrated with biosensing and amplification technologies, provide precise, rapid, and portable diagnostics, making on-site testing without the need for extensive infrastructure feasible, especially in underserved or rural areas. In contrast, traditional diagnostic methods, while still essential, are often limited by the need for costly equipment and skilled operators, restricting their accessibility.

View Article and Find Full Text PDF

The Coronavirus Disease 2019 (COVID-19) recently emerged as a life-threatening global pandemic that has ravaged millions of lives. The affected patients are known to frequently register numerous comorbidities induced by COVID-19 such as diabetes, asthma, cardiac arrest, hypertension, and neurodegenerative diseases, to name a few. The expensiveness and probability of false negative results of conventional screening tests often delay timely diagnosis and treatment.

View Article and Find Full Text PDF

CRISPR/Cas12a with Universal crRNA for Indiscriminate Virus Detection.

Molecules

December 2024

Biotecnovo (Beijing) Co., Ltd., Room 801 Suit C Hengtai Center, Building 3 Gate, 18 North Feng Road, Fengtai District, Beijing 100176, China.

Viruses, known for causing widespread biological harm and even extinction, pose significant challenges to public health. Virus detection is crucial for accurate disease diagnosis and preventing the spread of infections. Recently, the outstanding analytical performance of CRISPR/Cas biosensors has shown great potential and they have been considered as augmenting methods for reverse-transcription polymerase chain reaction (RT-PCR), which was the gold standard for nucleic acid detection.

View Article and Find Full Text PDF

Leveraging Synthetic Antibody-DNA Conjugates to Expand the CRISPR-Cas12a Biosensing Toolbox.

ACS Synth Biol

January 2025

Department of Chemical Science and Technologies, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy.

We report here the use of antibody-DNA conjugates (Ab-DNA) to activate the collateral cleavage activity of the CRISPR-Cas12a enzyme. Our findings demonstrate that Ab-DNA conjugates effectively trigger the collateral cleavage activity of CRISPR-Cas12a, enabling the transduction of antibody-mediated recognition events into fluorescence outputs. We developed two different immunoassays using an Ab-DNA as activator of Cas12a: the CRISPR-based immunosensing assay (CIA) for detecting SARS-CoV-2 spike S protein, which shows superior sensitivity compared with the traditional enzyme-linked immunosorbent assay (ELISA), and the CRISPR-based immunomagnetic assay (CIMA).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!